Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Nursing Home & Skilled Nursing Facility Experts

Analysis of: YM BioSciences USA Cleared By US FDA To Initiate Phase II Clinical Trial Of Nimotuzumab In Children With Inoperable, Recurrent Brain Cancer (www.medicalnewstoday.com)
Nimotuzumab is a humanized monoclonal antibody against EGFR. Initial results showed some response in patients with GBM and recurrent pediatric gliomas (ASCO 2007).  High grade gliomas have many genetic aberrations including amplification of EGFR, loss of the tumor-suppressor protein PTEN, overexpression...
Analysis of: Varian Medical Systems Receives FDA 510(k) Clearance for Smart Segmentation™ Tool That Dramatically Speeds Up Radiotherapy Treatment Planning (varian.mediaroom.com)
Varian's new Smart Segmentation Tool is an addition to their Eclipse planning system which aims to shorten planning time in intesity modulated radiation therapy (IMRT) cases.    Typically, IMRT cases require the planning physician to spend several hourse identifying target structures...
Analysis of: Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma (www.pipelinereview.com)
ALS-357 has shown pre-clinical success both in-vitro and in-vivo, and is now slated for phase I/II trials. Unfotunately this drug is targeting metastitic melanoma using a topical delivery vehicle.   While this has worked in a mouse, I'm not sure this will really work effectively in humans...
Glen McDaniel, MS, MBA, President and Chief Executive Officer
Glen McDaniel, MS, MBA, President and Chief Executive Officer
GM Global
Analysis of: MDs offer new services, for $3,600 yearly fee (www.boston.com)
It is important to look closely at the new niche called Concierge Medicine. It is obviously created out of  a special need and will prove lucrative for physicians who choose to go that route. But there are larger questions of access and ethics of exclusivity/ One has to consider whether this...
Glen McDaniel, MS, MBA, President and Chief Executive Officer
Glen McDaniel, MS, MBA, President and Chief Executive Officer
GM Global
Analysis of: Earl Reed Steps Down as LifeCare CEO; William Hamburg Named Interim CEO (www.carlyle.com)
The recent changes in leadership in the LTAC space is significant and suggests a tightening of operations. It is important to monitor the overall long term space as well as follow who goes where.  The changes are not insignificant, but may not be as ominous as they appear on the surface. Investors...
August 30, 2007
Where's the data??
Analysis of: Brain cancer therapy.(Therapeutic vaccine) (www.therapeuticsdaily.com)
Vaccines are an interesting concept in cancer therapeutics.   However, other than Guardasil, which prevents HPV infection and subsequent risk of cervical cancer, NO other vaccine has shown a true benefit in patients with active cancers.   Look at all the data in melanoma, which has...
Analysis of: Study Supports Simultaneous Technique for Breast-Conserving Radiotherapy (www.medscape.com)
Standard breast conserving therapy consists of breast conserving surgery followed by whole breast radiotherapy (to a dose of 45-50.4Gy), followed by a boost to the lumpectomy site of 10-16Gy for a total dose of 61-66Gy.    The boost is typically done after the completion of whole breast...
Analysis of: Medicaid moving to managed care plans (www.goupstate.com)
With skyrocketing enrollment nubers due to immagration and the "Graying of America", Federal and State Health Care Agencies will be compelled to move patients to managed care.
Analysis of: New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors (www.medicalnewstoday.com)
CMS's latests decision to not reimburse hospitals for medical errors and hospital acquired infections has been widely discussed on these newsgroups.   Simpy put, while medical errors and infections are unfortunate and can have adverse consequences, the key here is which of these events could...
Analysis of: BIOLINERX STARTS PHASE II TRIAL OF BL-1020 FOR SCHIZOPHRENIA. (www.therapeuticsdaily.com)
The fact that they are pushing the maximum dose indicates that the Phase I trials went well. The market is waiting for new classes of antpsychotics/schizophrenia agents due to the endo side effects associated with current market leaders.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 155

Analytics


Generated at 2009-01-07T19:00:58.307